CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $268,984, lower than 95% of all stocks globally
- PositionOperating margin is -109854.5%, lower than 95% of its Biotechnology peers (median -38%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.99BHKD891.40M · vs all stocks (USD)
Revenue (TTM)
2.11MHKD268.98K · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-75.86%vs all stocks
Market Capitalization
6.99BHKD891.40M · vs all stocks (USD)
Enterprise Value
7.65BHKD975.14M · vs all stocks (USD)
Price to Book (MRQ)
3.10xvs Biotechnology peers
Enterprise to Revenue
3.63Kxvs Biotechnology peers
Enterprise to EBITDA
-8.02xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-190.69%vs Biotechnology peers
Return on Equity (TTM)
-111.86%vs Biotechnology peers
Revenue (TTM)
2.11MHKD268.98K · vs all stocks (USD)
Revenue per Share (TTM)
0.00HKDUpdated Sep 20, 2026Quarterly Revenue Growth
57.10%vs Biotechnology peers
Gross Profit (TTM)
2.11MHKD268.98K · vs all stocks (USD)
EBITDA (TTM)
-954.05MHKD-121.61M · vs all stocks (USD)
Net Income (TTM)
-947.56MHKD-120.79M · vs all stocks (USD)
Operating Cash Flow (TTM)
-51.54MHKD-6.57M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-67.66MHKD-8.62M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-107.45MUSDvs all stocks (USD)
Pre-tax Income
-67.77MUSDFY2025 · Dec 31, 2025Income Tax Expense
-114.00KUSDFY2025 · Dec 31, 2025Net Income
-67.66MUSDFY2025 · Dec 31, 2025EBIT
-67.75MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-67.34MUSDFY2025 · Dec 31, 2025Research & Development
66.80MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
40.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.16MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
23.00KUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-11.24MUSDFY2025 · Dec 31, 2025Free Cash Flow
-11.44MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
40.15MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-67.77MUSDFY2025 · Dec 31, 2025Stock-based Compensation
57.78MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.14MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-110.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-197.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-18.00MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-197.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
431.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
78.36MUSDFY2025 · Dec 31, 2025Shares Outstanding
844.57MSharesUpdated Sep 20, 2026Float Shares
306.21MSharesUpdated Sep 20, 2026% Held by Insiders
55.74%vs all stocks
% Held by Institutions
5.37%vs all stocks
Total Cash (MRQ)
351.64MHKD44.82M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0530HKDUpdated Sep 20, 2026Total Debt (MRQ)
50.42MHKD6.43M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1530xvs Biotechnology peers
Current Ratio (MRQ)
4.29xvs Biotechnology peers
Book Value per Share (MRQ)
0.3843HKDUpdated Sep 20, 2026Total Assets
66.61MUSDvs all stocks (USD)
Total Current Assets
64.34MUSDFY2025 · Dec 31, 2025Total Liabilities
6.12MUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.27MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
98.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
6.02MUSDFY2025 · Dec 31, 2025Cash
30.85MUSDFY2025 · Dec 31, 2025Cash Equivalents
9.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
40.15MUSDFY2025 · Dec 31, 2025Other Short-term Investments
18.20MUSDFY2025 · Dec 31, 2025Inventory
110.00KUSDFY2025 · Dec 31, 2025Accounts Payable
836.00KUSDFY2025 · Dec 31, 2025Short-term Debt
664.00KUSDFY2025 · Dec 31, 2025Long-term Debt
98.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
84.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-411.91MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
60.49MUSDvs all stocks (USD)
52-Week Low
0.9000HKDUpdated Sep 20, 202652-Week High
9.58HKDUpdated Sep 20, 202652-Week Change
-75.86%vs all stocks
50-Day MA
1.22HKDUpdated Sep 20, 2026200-Day MA
2.13HKDUpdated Sep 20, 2026Avg 10-Day Volume
20.70KSharesUpdated Sep 20, 2026Avg 30-Day Volume
78.53KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-1.08HKDUpdated Sep 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -109854.5%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -1,098.545Industry median: -0.38Industry P5: -43.63Peers compared: 260
Return on assets is -190.7%, lower than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: -1.91Industry median: -0.20Industry P5: -0.83Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $268,984, lower than 95% of all stocks globallySignificant
Revenue (USD): 268,984.39Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ardelyx Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rigel Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
China Isotope & Radiation Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anhui Tatfook Technology Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Hebei Sailhero Environmental Protection Hi-Tech Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Finolex Industries Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity